Do analysts rate INBX or INDP?

Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 126.80%. Given Inhibrx Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Inhibrx Biosciences is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INBX or INDP more profitable?

Indaptus Therapeutics' return on equity of -302.89% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -83.48% Indaptus Therapeutics N/A -302.89% -203.49%

Do analysts prefer OMER or INDP?

Omeros currently has a consensus target price of $34.00, indicating a potential upside of 80.08%. Given Omeros' stronger consensus rating and higher probable upside, equities analysts plainly believe Omeros is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.71 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, OMER or INDP?

Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 14.75 Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A

Is OMER or INDP more profitable?

Omeros' return on equity of -164.92% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Indaptus Therapeutics N/A -302.89% -203.49%

Do analysts rate INDP or COAG?

Hemab Therapeutics has a consensus price target of $52.17, indicating a potential upside of 75.06%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hemab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has stronger valuation & earnings, INDP or COAG?

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A Hemab Therapeutics N/A N/A N/A -$24.78 N/A

Is INDP or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -302.89% -203.49% Hemab Therapeutics N/A N/A N/A

Do analysts recommend NBTX or INDP?

Nanobiotix presently has a consensus price target of $46.67, suggesting a potential upside of 117.16%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts clearly believe Nanobiotix is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, NBTX or INDP?

Indaptus Therapeutics has lower revenue, but higher earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 29.50 -$27.11M N/A N/A Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A

Is NBTX or INDP more profitable?

Nanobiotix's return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Indaptus Therapeutics N/A -302.89% -203.49%

Indaptus Therapeutics (INDP) Competitors

$2.28 -0.12 (-4.81%)

As of 11:33 AM Eastern

Compare

INDP vs. INBX, NKTR, OMER, COAG, and NBTX

Should you buy Indaptus Therapeutics stock or one of its competitors? Indaptus Therapeutics's main competitors and comparable companies include Inhibrx Biosciences (INBX), Nektar Therapeutics (NKTR), Omeros (OMER), Hemab Therapeutics (COAG), and Nanobiotix (NBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Indaptus Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Indaptus Therapeutics has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	986.01	-$140.05M	-$8.88	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for Inhibrx Biosciences and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.79 beat Inhibrx Biosciences' score of 0.61 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibrx Biosciences	Positive
Indaptus Therapeutics	Very Positive

Indaptus Therapeutics' return on equity of -302.89% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Inhibrx Biosciences has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 126.80%. Given Inhibrx Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Inhibrx Biosciences is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Inhibrx Biosciences beats Indaptus Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Indaptus Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Nektar Therapeutics presently has a consensus price target of $130.67, indicating a potential upside of 244.59%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nektar Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Indaptus Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	23.44	-$164.08M	-$6.70	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

In the previous week, Nektar Therapeutics had 13 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 14 mentions for Nektar Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.79 beat Nektar Therapeutics' score of 0.48 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nektar Therapeutics	Neutral
Indaptus Therapeutics	Very Positive

Summary

Nektar Therapeutics beats Indaptus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Omeros' return on equity of -164.92% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Omeros has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Omeros currently has a consensus target price of $34.00, indicating a potential upside of 80.08%. Given Omeros' stronger consensus rating and higher probable upside, equities analysts plainly believe Omeros is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

48.8% of Omeros shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.75
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

In the previous week, Omeros had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for Omeros and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.79 beat Omeros' score of 0.37 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Omeros	Neutral
Indaptus Therapeutics	Very Positive

Summary

Omeros beats Indaptus Therapeutics on 13 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Hemab Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Hemab Therapeutics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-302.89%	-203.49%
Hemab Therapeutics	N/A	N/A	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Hemab Therapeutics had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Hemab Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.79 beat Hemab Therapeutics' score of 0.63 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Indaptus Therapeutics	Very Positive
Hemab Therapeutics	Positive

Hemab Therapeutics has a consensus price target of $52.17, indicating a potential upside of 75.06%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Hemab Therapeutics beats Indaptus Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Indaptus Therapeutics has lower revenue, but higher earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	29.50	-$27.11M	N/A	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

Nanobiotix's return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Indaptus Therapeutics	N/A	-302.89%	-203.49%

In the previous week, Nanobiotix and Nanobiotix both had 1 articles in the media. Indaptus Therapeutics' average media sentiment score of 1.79 beat Nanobiotix's score of 0.89 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nanobiotix	Positive
Indaptus Therapeutics	Very Positive

Nanobiotix presently has a consensus price target of $46.67, suggesting a potential upside of 117.16%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts clearly believe Nanobiotix is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nanobiotix has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nanobiotix beats Indaptus Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$303.12M	$3.88B	$7.25B	$13.04B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-0.36	13.03	275.44	25.51
Price / Sales	N/A	1,148.01	562.05	79.58
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.63	16.75	10.64	6.00
Net Income	-$20.85M	-$22.65M	$3.49B	$380.50M
7 Day Performance	0.66%	-4.89%	-3.21%	-3.35%
1 Month Performance	-27.55%	-12.84%	-7.65%	-6.23%
1 Year Performance	-45.31%	7.43%	2.92%	-3.96%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	0.8831 of 5 stars	$2.28 -4.8%	N/A	-40.7%	$303.12M	N/A	N/A	5	Positive News Gap Down
INBX Inhibrx Biosciences	3.2938 of 5 stars	$93.36 -0.1%	$197.50 +111.5%	+153.3%	$1.37B	$1.30M	N/A	110
NKTR Nektar Therapeutics	3.0736 of 5 stars	$40.26 +0.9%	$138.50 +244.0%	-33.9%	$1.36B	$55.23M	N/A	63	Analyst Forecast
OMER Omeros	3.7819 of 5 stars	$18.75 +1.3%	$34.00 +81.3%	+350.6%	$1.34B	N/A	14.65	175	Analyst Forecast
COAG Hemab Therapeutics	2.9737 of 5 stars	$28.70 +1.2%	$51.40 +79.1%	N/A	$1.33B	N/A	N/A	59	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. INBX, NKTR, OMER, COAG, and NBTX

How does Indaptus Therapeutics compare to Inhibrx Biosciences?

Summary

How does Indaptus Therapeutics compare to Nektar Therapeutics?

Summary

How does Indaptus Therapeutics compare to Omeros?

Summary

How does Indaptus Therapeutics compare to Hemab Therapeutics?

Summary

How does Indaptus Therapeutics compare to Nanobiotix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. INBX, NKTR, OMER, COAG, and NBTX

How does Indaptus Therapeutics compare to Inhibrx Biosciences?

Which has higher valuation and earnings, INBX or INDP?

Does the media favor INBX or INDP?

Is INBX or INDP more profitable?

Which has more risk & volatility, INBX or INDP?

Do analysts rate INBX or INDP?

Do insiders & institutionals have more ownership in INBX or INDP?

Summary

How does Indaptus Therapeutics compare to Nektar Therapeutics?

Is NKTR or INDP more profitable?

Do analysts recommend NKTR or INDP?

Do insiders and institutionals believe in NKTR or INDP?

Which has more volatility & risk, NKTR or INDP?

Which has better valuation & earnings, NKTR or INDP?

Does the media prefer NKTR or INDP?

Summary

How does Indaptus Therapeutics compare to Omeros?

Is OMER or INDP more profitable?

Which has more risk and volatility, OMER or INDP?

Do analysts prefer OMER or INDP?

Do institutionals and insiders have more ownership in OMER or INDP?

Which has preferable earnings and valuation, OMER or INDP?

Does the media prefer OMER or INDP?

Summary

How does Indaptus Therapeutics compare to Hemab Therapeutics?

Which has stronger valuation & earnings, INDP or COAG?

Is INDP or COAG more profitable?

Do insiders and institutionals believe in INDP or COAG?

Does the media favor INDP or COAG?

Do analysts rate INDP or COAG?

Summary

How does Indaptus Therapeutics compare to Nanobiotix?

Which has higher earnings and valuation, NBTX or INDP?

Is NBTX or INDP more profitable?

Does the media prefer NBTX or INDP?

Do analysts recommend NBTX or INDP?

Which has more volatility & risk, NBTX or INDP?

Do institutionals & insiders hold more shares of NBTX or INDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools